BioCentury
ARTICLE | Clinical News

Novavax down after Phase III miss for RSV vaccine in infants

February 28, 2019 11:01 PM UTC

Novavax Inc. (NASDAQ:NVAX) lost $1.42 (67%) to $0.71 on Thursday after reporting that its ResVax RSV vaccine missed the primary endpoint in the Phase III Prepare trial to prevent respiratory syncytial virus infection in infants via maternal immunization.

In the trial's per protocol population (n=4,195), ResVax showed a vaccine efficacy of 39.4% vs. placebo in reducing the incidence of medically significant RSV lower respiratory tract infections through 90 days of life...

BCIQ Company Profiles

Novavax Inc.